CRESTOR Demonstrates CV Risk Reduction in a Large Statin Outcomes Study
New data from the JUPITER study demonstrated that CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
Results also showed that for patients in the trial taking rosuvastatin:
- the combined risk of heart attack, stroke or CV death was reduced by nearly half (47%, p<0.001).
- risk of heart attack was cut by more than half (54%, p<0.001).
- risk of stroke was cut by nearly half (48%, p=0.002).
- total mortality was significantly reduced by 20% (p=0.02).
These results were accompanied by a median LDL-C reduction of 50% (p<0.001) resulting in an on-treatment median LDL-C of 55 mg/dL.
On the basis of the data, if the results are projected over a period of 5 years, 25 patients would need to be treated to prevent one major cardiovascular event (NNT=25).
The JUPITER results were published online by the New England Journal of Medicine.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
UCLA scientists map all mammalian gene interactions

How molecules measure embryo size
Cramp
Calcidiol
Temple_(anatomy)

A new contrast agent for MRI - New iron oxide nanoparticles could help avoid a rare side effect caused by current contrast agents
DNA-coated nanotubes help kill tumors without harm to surrounding tissue
RETSCH relocates to new, larger premises
Sensitive new assay detects hepatitis B infection in single liver cells and serum
International_Osteoporosis_Foundation
Prion disease detected soon after infection and in surprising place in mouse brains
